Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm

Mattia Vinciguerra, Silvia Romiti, Khalil Fattouch, Antonio De Bellis, Ernesto Greco, Mattia Vinciguerra, Silvia Romiti, Khalil Fattouch, Antonio De Bellis, Ernesto Greco

Abstract

The severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) outbreak is a public health emergency affecting different regions around the world. The lungs are often damaged due to the presence of Sars-CoV-2 binding receptor ACE2 on epithelial alveolar cells. Severity of infection varies from complete absence of symptomatology to more aggressive symptoms, characterized by sudden acute respiratory distress syndrome (ARDS), multiorgan failure, and sepsis, requiring treatment in intensive care unit (ICU). It is not still clear why the immune system is not able to efficiently suppress viral replication in a small percentage of patients. It has been documented as pathological conditions affecting the cardiovascular system, strongly associated to atherosclerotic progression, such as heart failure (HF), coronary heart disease (CHD), hypertension (HTN) and diabetes mellitus (DM), could serve as predictive factors for severity and susceptibility during Sars-CoV-2 infection. Atherosclerotic progression, as a chronic inflammation process, is characterized by immune system dysregulation leading to pro-inflammatory patterns, including interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), and IL-1β. Reviewing immune system and inflammation profiles in atherosclerosis and laboratory results reported in severe COVID-19 infections, we hypothesized a pathogenetic correlation. Atherosclerosis may be an ideal pathogenetic substrate for high viral replication ability, leading to adverse outcomes, as reported in patients with cardiovascular factors. The level of atherosclerotic progression may affect a different degree of severe infection; in a vicious circle, feeding itself, Sars-CoV-2 may exacerbate atherosclerotic evolution due to excessive and aberrant plasmatic concentration of cytokines.

Keywords: COVID-19; Sars-CoV-2; atherosclerosis; cytokine; pathogenesis of Sars-CoV-2.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Proposed pathogenetic correlation between atherosclerosis and severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2).

References

    1. Lauer S.A., Grantz K.H., Bi Q., Jones F.K., Zheng Q., Meredith H.R., Azman A.S., Reich N.G., Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med. 2020;172:577–582. doi: 10.7326/M20-0504.
    1. Hu Z., Song C., Xu C., Jin G., Chen Y., Xu X., Ma H., Chen W., Lin Y., Zheng Y., et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci. China Life Sci. 2020;63:706–711. doi: 10.1007/s11427-020-1661-4.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Fan G., Xu J., Gu X., Cheng Z., Yu T., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zhang L., Yu Z., Fang M., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Resp. Med. 2020;8:475–481. doi: 10.1016/S2213-2600(20)30079-5.
    1. Wu Z., Mc Googan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.
    1. Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection—A review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect. 2020;9:727–732. doi: 10.1080/22221751.2020.1746199.
    1. Zhou Y., Fu B., Zheng X., Wang D., Zhao C., Qi Y., Sun R., Tian Z., Xu X., Wei H. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev. 2020;7:998–1002. doi: 10.1093/nsr/nwaa041.
    1. Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–590. doi: 10.1007/s00134-020-05985-9.
    1. Fu Y., Cheng Y., Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol. Sin. 2020:1–6. doi: 10.1007/s12250-020-00207-4.
    1. Ludvigsson J.F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088–1095. doi: 10.1111/apa.15270.
    1. Zhao X., Zhang B., Li P., Ma C., Gu J., Hou P., Guo Z., Wu H., Bai Y. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: A systematic review and meta-analysis. MedRxiv. 2020 doi: 10.1101/2020.03.17.20037572.
    1. Wu D., Wu T., Liu Q., Yang Z. The SARS-CoV-2 outbreak: What we know. Int. J. Infect. Dis. 2020;94:44–48. doi: 10.1016/j.ijid.2020.03.004.
    1. Chen Y., Li L. SARS-CoV-2: Virus dynamics and host response. Lancet Infect. Dis. 2020;20:515–516. doi: 10.1016/S1473-3099(20)30235-8.
    1. Cascella M., Rajnik M., Cuomo A., Dulebohn S.C., Di Napoli R. StatPearls. StatPearls Publishing; St. Petersburg, Russia: 2020. Features, evaluation and treatment coronavirus (COVID-19)
    1. Verdecchia P., Cavallini C., Spanevello A., Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur. J. Intern. Med. 2020;76:14–20. doi: 10.1016/j.ejim.2020.04.037.
    1. Vinciguerra M., Greco E. Sars-CoV-2 and black population: ACE2 as shield or blade? Infect. Genet. Evol. 2020;84:104361. doi: 10.1016/j.meegid.2020.104361.
    1. Van de Veerdonk F.L., Netea M.G., van Deuren M., van der Meer J.W., de Mast Q., Brüggemann R.J., van der Hoeven H. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife. 2020;9:e57555. doi: 10.7554/eLife.57555.
    1. Risitano A.M., Mastellos D.C., Huber-Lang M., Yancopoulou D., Garlanda C., Ciceri F., Lambris J.D. Complement as a target in COVID-19? Nat. Rev. Immunol. 2020;20:343–344. doi: 10.1038/s41577-020-0320-7.
    1. Chen L., Liu H.G., Liu W., Liu J., Liu K., Shang J., Deng Y., Wei S. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin. J. Tuberc. Resp. Dis. 2020;43:E005.
    1. Han H., Yang L., Liu R., Liu F., Wu K.-L., Li J., Liu X.-H., Zhu C. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin. Chem. Lab. Med. (CCLM) 2020;58:1116–1120. doi: 10.1515/cclm-2020-0188.
    1. Wolf D., Ley K. Immunity and Inflammation in Atherosclerosis. Circ. Res. 2019;124:315–327. doi: 10.1161/CIRCRESAHA.118.313591.
    1. Deanfield J., Halcox J., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2017;115:1285–1295. doi: 10.1161/CIRCULATIONAHA.106.652859.
    1. Monteil V., Kwon H., Prado P., Hagelkrüys A., Wimmer R.A., Stahl M., Leopoldi A., Garreta E., Del Pozo C.H., Prosper F., et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–913. doi: 10.1016/j.cell.2020.04.004.
    1. Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418. doi: 10.1016/S0140-6736(20)30937-5.
    1. Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood J. Am. Soc. Hematol. 2020;135:2033–2040.
    1. Carsana L., Sonzogni A., Nasr A., Rossi R.S., Pellegrinelli A., Zerbi P., Rech R., Colombo R., Antinori S., Corbellino M., et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. Lancet Infect. Dis. 2020 doi: 10.1016/S1473-3099(20)30434-5.
    1. Magro C., Mulvey J.J., Berlin D., Nuovo G., Salvatore S., Harp J., Baxter-Stoltzfus A., Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl. Res. 2020;220:1–13. doi: 10.1016/j.trsl.2020.04.007.
    1. Taleb S. Inflammation in atherosclerosis: L’inflammation dans l’athérosclérose. Arch. Cardiovasc. Dis. 2016;109:708–715. doi: 10.1016/j.acvd.2016.04.002.
    1. Abbasi J. Cardiovascular Corner—Stable Coronary Artery Disease, An LDL “Vaccine,” and Anti-inflammatories. JAMA. 2020;323:1233–1234. doi: 10.1001/jama.2019.20983.
    1. Zhu Y., Xian X., Wang Z., Bi Y., Chen Q., Han X., Tang D., Chen R. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules. 2018;8:80. doi: 10.3390/biom8030080.
    1. Li B., Li W., Li X., Zhou H. Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis. Curr. Pharm. Des. 2017;23:1216–1227. doi: 10.2174/1381612822666161230142931.
    1. Miteva K., Madonna R., De Caterina R., Van Linthout S. Innate and adaptive immunity in atherosclerosis. Vasc. Pharm. 2018;107:67–77. doi: 10.1016/j.vph.2018.04.006.
    1. Wildgruber M., Aschenbrenner T., Wendorff H., Czubba M., Glinzer A., Haller B., Schiemann M., Zimmermann A., Berger H., Eckstein H.-H., et al. The “intermediate” CD14++ CD16+ monocyte subset increases in severe peripheral artery disease in humans. Sci. Rep. 2016;6:1–8. doi: 10.1038/srep39483.
    1. Hovland A., Jonasson L., Garred P., Yndestad A., Aukrust P., Lappegard K.T., Espevik T., Mollnes T.E. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis. 2015;241:480–494. doi: 10.1016/j.atherosclerosis.2015.05.038.
    1. Tabas I., Lichtman A.H. Monocyte-Macrophages and T Cells in Atherosclerosis. Immunity. 2017;47:621–634. doi: 10.1016/j.immuni.2017.09.008.
    1. Hedrick C.C. Lymphocytes in atherosclerosis. Arter. Thromb. Vasc. Biol. 2015;35:253–257. doi: 10.1161/ATVBAHA.114.305144.
    1. Sima P., Vannucci L., Vetvicka V. Atherosclerosis as autoimmune disease. Ann. Transl. Med. 2018;6:116. doi: 10.21037/atm.2018.02.02.
    1. Maganto-García E., Tarrio M.L., Grabie N., Bu D.-X., Lichtman A.H. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation. 2011;124:185–195. doi: 10.1161/CIRCULATIONAHA.110.006411.
    1. Rial J.G., Tuala M.J.C., Calle I.R., Carballa A.G., Lopez M.C., Tenreiro C.R., Urbieta A.D., Velasco C.R., Nunez N.R., Pena R.T., et al. Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology. medRxiv. 2020 doi: 10.1101/2020.06.02.20120295.
    1. Wang H., Yuan Z., Pavel M.A., Hansen S. Cholesterol and COVID19 lethality in elderly. bioRxiv. 2020 doi: 10.1101/2020.05.09.086249.
    1. Cai T., Zhang Y., Ho Y.L., Link N., Sun J., Huang J., Cai A., Damrauer S., Ahuja Y., Honerlaw J., et al. Association of interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy: A phenome-wide association study. JAMA Cardiol. 2018;3:849–857. doi: 10.1001/jamacardio.2018.2287.
    1. Ridker P.M., Lüscher T.F. Anti-inflammatory therapies for cardiovascular disease. Eur. Heart J. 2014;35:1782–1791. doi: 10.1093/eurheartj/ehu203.
    1. Ridker P.M. From C-Reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ. Res. 2016;118:145–156. doi: 10.1161/CIRCRESAHA.115.306656.
    1. Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., Fonseca F., Nicolau J., Koenig W., Anker S.D., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017;377:1119–1131. doi: 10.1056/NEJMoa1707914.
    1. Abbate A., Van Tassell B.W., Biondi-Zoccai G.G.L., Kontos M.C., Grizzard J.D., Spillman D.W., Oddi C., Roberts C.S., Melchior R.D., Mueller G.H., et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2)(VCU-ART2) pilot study] Am. J. Cardiol. 2013;111:1394–1400. doi: 10.1016/j.amjcard.2013.01.287.
    1. Morton A.C., Rothman A., Greenwood J.P., Gunn J., Chase A., Clarke B., Hall I.P., Fox K., Foley C., Banya W., et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA Heart Study. Eur. Heart J. 2015;36:377–384. doi: 10.1093/eurheartj/ehu272.
    1. Sarwar N., Butterworth A.S., Freitag D.F., Gregson J., Willeit P., Gorman N.N., Gao P., Saleheen D., Rendon A., Nelson C.P., et al. IL6R Genetics Consortium Emerging Risk Factors Collaboration: Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205–1213. doi: 10.1016/S0140-6736(11)61931-4.
    1. Cardillo C., Schinzari F., Melina D., Zoli A., Ferraccioli G., Mores N., Mettimano M. Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin. Pharmacol. Ther. 2006;80:275–281. doi: 10.1016/j.clpt.2006.05.011.
    1. Taguchi H., Nishi K., Suzuki T., Okano Y. Anti-atherosclerotic effects of etanercept in Rheumatoid Arthritis Patients. Jpn. J. Clin. Immunol. 2012;35:183–187. doi: 10.2177/jsci.35.183.
    1. Seriolo B., Fasciolo D., Paolino S., Sulli A., Cutolo M. Effects of anti-TNF-α treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N. Y. Acad. Sci. 2006;1069:414–419. doi: 10.1196/annals.1351.039.
    1. Tam L.S., Kitas G.D., Gonźlez-gay M.A. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology. 2014;53:1108–1119. doi: 10.1093/rheumatology/ket454.
    1. Nidorf S.M., Eikelboom J., Budgeon C., Thompson P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 2013;61:404–410. doi: 10.1016/j.jacc.2012.10.027.
    1. Cavalli G., De Luca G., Campochiaro C., Della-Torre E., Ripa M., Canetti D., Oltolini C., Castiglioni B., Din C.T., Boffini N., et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325–e331. doi: 10.1016/S2665-9913(20)30127-2.
    1. Aouba A., Baldolli A., Geffray L., Verdon R., Bergot E., Martin-Silva N., Justet A. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: Case series. Ann. Rheum. Dis. 2020 doi: 10.1136/annrheumdis-2020-217706.
    1. Bonow R.O., Fonarow G.C., O’Gara P.T., Yancy C.W. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1105.
    1. Smeeth L., Thomas S.L., Hall A., Hubbard R.B., Farrington C.P., Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 2004;351:2611–2618. doi: 10.1056/NEJMoa041747.
    1. Albiero R., Seresini G. Atherosclerotic spontaneous coronary artery dissection (A-SCAD) in a patient with COVID-19: Case report and possible mechanisms. Eur. Heart J. Case Rep. 2020 doi: 10.1093/ehjcr/ytaa133.
    1. Wu Q., Zhou L., Sun X., Yan Z., Hu C., Wu J., Xu L., Li X., Liu H., Yin P., et al. Altered lipid metabolism in recovered sars patients twelve years after infection. Sci. Rep. 2017;7:1–12. doi: 10.1038/s41598-017-09536-z.
    1. Sun J., Yu H., Liu H., Pu D., Gao J., Jin X., Liu X., Yan A. Correlation of pre-operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents. J. Clin. Lab. Anal. 2019;34:e23108. doi: 10.1002/jcla.23108.
    1. Chen C., Zhou Y., Wang D.W. SARS-CoV-2: A potential novel etiology of fulminant myocarditis. Herz. 2020;45:230–232. doi: 10.1007/s00059-020-04909-z.
    1. Buggey J., ElAmm C.A. Myocarditis and cardiomyopathy. Curr. Opin. Cardiol. 2018;33:341–346. doi: 10.1097/HCO.0000000000000514.
    1. Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;2020:e200950. doi: 10.1001/jamacardio.2020.0950.
    1. Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020;2020:e201017. doi: 10.1001/jamacardio.2020.1017.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj